The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Inhibition of Angiogenesis by Aβ Peptides
Abstract
Abeta peptides are naturally occurring peptides forming beta-sheet aggregates that constitute an integral component of senile plaques and vascular deposits in Alzheimer's disease. Since several peptides adopting a beta-sheet conformation have been shown to be anti-angiogenic, we investigated the effect of Abeta on angiogenesis. We show that in vitro, Abeta dose-dependently inhibits the formation of capillaries by human brain endothelial cells plated on Matrigel and stimulates capillary degeneration at high doses. Preparations of Abeta peptides containing a higher content of beta-sheet structures are more potently anti-angiogenic in vitro. Ex vivo, Abeta dose-dependently opposes angiogenesis in rat aortae and in human middle cerebral arteries. In vivo, Abeta dose dependently inhibits angiogenesis in the chick chorioallantoic membrane assay and suppresses bFGF-induced blood vessel formation in the corneal micropocket and Matrigel plug assays. Since angiogenesis is required for tumor growth, we explored the effect of Abeta on human glioblastoma (U87MG) and human lung adenocarcinoma (A549) tumors. We show that intra-tumoral injection of Abeta potently inhibits the growth and vascularization of human glioblastoma and human lung adenocarcinoma tumor xenografts in nude mice. Similarly to the intra-tumoral injection regimen, Abeta delivered intraperitoneally also suppressed the growth of human lung adenocarcinoma tumor xenografts. Altogether our data show that Abeta is an angiogenesis inhibitor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo, injection of Aβ into mice transplanted with human glioblastoma and lung adenocarcinoma suppresses the tumor growth.410”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [410]
Citations
Cites
[18] Quantification of β-sheet amyloid fibril structures with thioflavin T
LeVine, H. (1999) · Methods in Enzymology · doi:10.1016/s0076-6879(99)09020-5 · Cited by 1,365
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Soto, C. A., Sigurdsson, E. M., Morelli, L., Kumar, R., Castaño, E. M., & Frangione, B. (1998) · Nature Medicine · doi:10.1038/nm0798-822 · Cited by 874
Jones, M. K., Wang, H., Peskar, B. M., Levin, E. R., Itani, R. M., Sarfeh, I. J., & Tarnawski, A. S. (1999) · Nature Medicine · doi:10.1038/70995 · Cited by 826
Passaniti, A., Taylor, R. M., Пили, Р., Guo, Y., Long, P., Haney, J. A., Pauly, R. R., Grant, D. S., & Martin, G. R. (1992) · PubMed · Cited by 806
The basement membrane in pathology.
Martínez-Hernández, A., & Amenta, P. S. (1983) · PubMed · Cited by 656
Ellis, R. J., Olichney, J. M., Thal, L. J., Mirra, S. S., Morris, J. C., Beekly, D., & Heyman, A. (1996) · Neurology · doi:10.1212/wnl.46.6.1592 · Cited by 561
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Pan, Q., Kleer, C. G., van Golen, K. L., Irani, J., Bottema, K. M., Bias, C., Carvalho, M. D., Mesri, E. A., Robins, D. M., Dick, R. D., et al. (2002) · PubMed · Cited by 434
Crystal Structure of Human BPI and Two Bound Phospholipids at 2.4 Angstrom Resolution
Beamer, L. J., Carroll, S. F., & Eisenberg, D. S. (1997) · Science · doi:10.1126/science.276.5320.1861 · Cited by 356
Buée, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., & Fillit, H. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294173 · Cited by 331
Atwood, C., Obrenovich, M. E., Liu, T., Chan, H., Perry, G. L., Smith, M. A., & Martins, R. N. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00174-7 · Cited by 297
Halverson, K. J., Fraser, P. E., Kirschner, D. A., & Lansbury, P. T. (1990) · Biochemistry · doi:10.1021/bi00463a003 · Cited by 292
Fezoui, Y., Hartley, D. M., Harper, J. D., Khurana, R., Walsh, D. M., Condron, M. M., Selkoe, D. J., Lansbury, P. T., Fink, A. L., & Teplow, D. B. (2000) · Amyloid · doi:10.3109/13506120009146831 · Cited by 259
Miravalle, L., Tokuda, T., Chiarle, R., Giaccone, G., Bugiani, O., Tagliavini, F., Frangione, B., & Ghiso, J. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003154200 · Cited by 237
Cerebral Hypoperfusion Generates Cortical Watershed Microinfarcts in Alzheimer Disease
Suter, O.-C., Sunthorn, T., Kraftsik, R., Straubel, J., Pushpa Darekar, B., Khalili, K., & Judith Miklossy, A. (2002) · Stroke · doi:10.1161/01.str.0000024523.82311.77 · Cited by 235
Differential degeneration of the cerebral microvasculature in Alzheimerʼs disease
Kalaria, R. N., & Hedera, P. (1995) · Neuroreport · doi:10.1097/00001756-199502000-00018 · Cited by 216
Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution
Hohenester, E., Sasaki, T., Olsen, B. R., & Timpl, R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1656 · Cited by 215
Cláudio, L. (1995) · Acta Neuropathologica · doi:10.1007/s004010050386 · Cited by 210
The Blood‐Brain Barrier and Cerebrovascular Pathology in Alzheimer's Disease
Kalaria, R. N. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07821.x · Cited by 196
Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia
Kalaria, R. N., Cohen, D., Premkumar, D. R., Nag, S., LaManna, J. C., & Lust, W. D. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00190-9 · Cited by 190
Altered angioarchitecture in selected areas of brains with Alzheimer's disease
Fischer, V. W., Siddiqi, A., & Yusufaly, Y. (1990) · Acta Neuropathologica · doi:10.1007/bf00294246 · Cited by 190
Brain Microvascular Changes in Alzheimer's Disease and Other Dementiasa
Buée, L., Hof, P. R., & Delacourte, A. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48457.x · Cited by 166
Increased collagen content of cerebral microvessels in Alzheimer's disease
Kalaria, R. N., & Pax, A. B. (1995) · Brain Research · doi:10.1016/0006-8993(95)01250-8 · Cited by 157
Thickening of the basement membrane of cortical capillaries in Alzheimer's disease
Mancardi, G., Perdelli, F., Rivano, C., Leonardi, A., & Bugiani, O. (1980) · Acta Neuropathologica · doi:10.1007/bf00692225 · Cited by 147
Nicosia, R. F., Lin, Y. J., Hazelton, D. A., & Qian, X. (1997) · Europe PMC (PubMed Central) · Cited by 136
Takano, S., Gately, S. T., Neville, M. E., Herblin, W. F., Gross, J. L., Engelhard, H. H., Perricone, M. A., Eidsvoog, K., & Brem, S. S. (1994) · PubMed · Cited by 131
Self-citationEndostatin Inhibits Microvessel Formation in the ex Vivo Rat Aortic Ring Angiogenesis Assay
Kruger, E. A., Duray, P. H., Tsokos, M., Venzon, D. J., Libutti, S. K., Dixon, S. C., Rudek, M. A., Pluda, J. M., Allegra, C. J., & Figg, W. D. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.2018 · Cited by 91
Kuo, Y., Crawford, F., MULLAN, M. J., Kokjohn, T. A., Emmerling, M. R., Weller, R. O., & Roher, A. E. (2000) · Molecular Medicine · doi:10.1007/bf03401785 · Cited by 68
Self-citationAnti-tumor activity of the novel angiogenesis inhibitor anginex
Dings, R. P. M., van der Schaft, D. W. J., Hargittai, B., Haseman, J., Griffioen, A. W., & Mayo, K. H. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00015-6 · Cited by 68
Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway
Paris, D., Town, T., Mori, T., Parker, T. A., Humphrey, J., & MULLAN, M. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00111-6 · Cited by 66
Self-citationKranenburg, O., Kroon-Batenburg, L. M. J., Reijerkerk, A., Wu, Y., Voest, E. E., & Gebbink, M. F. B. G. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00218-7 · Cited by 61
Mayo, K. H., Roongta, V. A., Ilyina, E. E., Milius, R. P., Barker, S., Quinlan, C. A., Rosa, G. L., & Daly, T. J. (1995) · Biochemistry · doi:10.1021/bi00036a012 · Cited by 60
beta-Sheet is the bioactive conformation of the anti-angiogenic anginex peptide
Dings, R. P. M., Arroyo, M., Lockwood, N. A., van Eijk, L. I., Haseman, J., Griffioen, A. W., & Mayo, K. H. (2003) · Biochemical Journal · doi:10.1042/bj20030295 · Cited by 54
Nicosia, R. F., Bonanno, E., & Villaschi, S. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90022-9 · Cited by 52
Baeyens, K., Bondt, H. L. D., Raeymaekers, A., Fiers, W. C., & Ranter, C. J. D. (1999) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998018435 · Cited by 51
Clarke, K., Lee, F.-T., Brechbiel, M. W., Smyth, F. E., Old, L. J., & Scott, A. M. (2000) · PubMed · Cited by 50
Takenouchi, T., & Munekata, E. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00235-x · Cited by 44
β-Amyloid Peptide Produced in Vitro Is Degraded by Proteinases Released by Cultured Cells
Naidu, A., Quon, D. H., & Cordell, B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1369 · Cited by 40
Pro-inflammatory effect of freshly solubilized β-amyloid peptides in the brain
Paris, D., Townsend, K. P., Obregon, D. F., Humphrey, J., & Mullan, M. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00111-9 · Cited by 40
Self-citationGyorffy, S., Palmer, K., & Gauldie, J. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61790-7 · Cited by 34
Paris, D., Townsend, K. P., Humphrey, J., Obregon, D. F., Yokota, K., & MULLAN, M. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00660-8 · Cited by 31
Self-citationAlzheimer's β‐amyloid vasoactivity: identification of a novel β‐amyloid conformational intermediate
Crawford, F., Soto, C. A., Suo, Z., Fang, C., Parker, T. A., Sawar, A., Frangione, B., & Mullan, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01170-3 · Cited by 26
Self-citationA diaminoantraquinone inhibitor of angiogenesis.
Takano, S., Gately, S. T., Jiang, J., & Brem, S. S. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23786-7 · Cited by 15
Self-citationJaworski, J., Figiel, I., Prószyński, T. J., & Kaczmarek, L. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20000615)60:6 · Cited by 9
Cited by
Sorted by citations
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
Neurovascular mechanisms of Alzheimer's neurodegeneration
Zlokovic, B. V. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.02.001 · Cited by 770
Review: Cerebral microvascular pathology in ageing and neurodegeneration
Brown, W. R., & Thore, C. R. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01139.x · Cited by 749
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3966 · Cited by 689
Metadata
- Authors
- Paris, D., Townsend, K., Quadros, A., Humphrey, J., Sun, J., Brem, S., Wotoczek-Obadia, M., DelleDonne, A., Patel, N., Obregon, D. F., Crescentini, R., Abdullah, L., Coppola, D., Rojiani, A. M., Crawford, F., Sebti, S. M., & Mullan, M.
- Affiliations
- Roskamp Institute (US)
- Moffitt Cancer Center (US)
- Corresponding author
- Mullan, Michael
- ORCID
- Venue
- Angiogenesis
- Published
- 2004-03
- Volume
- 7
- Issue
- 1
- Pages
- 75-85
- ISSN
- 0969-6970 (ISSN-L)
- 1573-7209
- OpenAlex
- W2599367511
- Cited by
- 148
- References
- 45
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 9 · 2023: 8 · 2022: 6 · 2021: 5 · 2020: 6 · 2019: 6 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 8 · 2014: 6 · 2013: 7 · 2012: 7
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Angiogenesis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- amyloid-beta, angiogenesis inhibition, β-sheet conformation, Alzheimer's disease, brain endothelial cells, capillary degeneration, tumor vascularization, glioblastoma, lung adenocarcinoma, tumor xenografts, anti-angiogenic peptides
- MeSH terms
- Animals, Cells, Cultured, Endothelium, Vascular, Female, Humans, Mice, Nude, Neoplasm Transplantation, Neoplasms, Experimental, Neovascularization, Pathologic, Peptide Fragments, Transplantation, Heterologous, Amyloid beta-Peptides, Treatment Outcome, Neovascularization, Physiologic, Angiogenesis Inhibitors, Middle Cerebral Artery, Cell Line, Tumor, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
